InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（2 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the complete record of transactions filed by Esposito Pamela, Directeur Commercial. Director active across 3 companies, notably Replimune Group, Inc.. In total, 20 filings have been logged. Breakdown: 0 buy · 2 sells. Total volume traded: €148k. Activity tracked since 14 January 2021. The latest transaction was disclosed on 20 March 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Esposito Pamela
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
2,500 股@ US$49.10100.0% 占其流量Common StockSEC:0001193125-26-118032:0
2,500 股@ US$49.109.2% 占其流量Common StockSEC:0001193125-26-061686:0
3,000 股@ US$31.207.1% 占其流量Common StockSEC:0001193125-26-016934:0
12,563 股@ US$49.1055.2% 占其流量Common StockSEC:0001193125-25-323090:0
5,000 股@ US$29.5530.5% 占其流量Common StockSEC:0000950170-25-081201:0
2,500 股@ US$29.5523.7% 占其流量Common StockSEC:0000950170-24-132401:0
8,500 股@ US$29.5576.3% 占其流量Common StockSEC:0000950170-24-107458:0
5,358 股@ US$3.303.8% 占其流量Common StockSEC:0001104659-23-100560:0
13,600 股@ US$3.309.6% 占其流量Common StockSEC:0001104659-23-094997:0
1,400 股@ US$3.301.0% 占其流量Common StockSEC:0001104659-23-092111:0
15,000 股@ US$3.3010.5% 占其流量Common StockSEC:0001104659-23-080113:0
5,966 股@ US$18.0523.1% 占其流量Common StockSEC:0001104659-23-062372:0
40,000 股0Common StockSEC:0001104659-23-041727:0
15,000 股@ US$1.013.3% 占其流量Common StockSEC:0001104659-22-126741:0
3,507 股@ US$14.5914.0% 占其流量Common StockSEC:0001104659-22-062610:0
22,750 股0Common StockSEC:0001104659-22-042762:0
4,200 股@ US$15.5015.7% 占其流量Common StockSEC:0001104659-21-101719:0
4,862 股@ US$1.011.2% 占其流量Common StockSEC:0001104659-21-095084:0
4,600 股@ US$1.011.1% 占其流量Common StockSEC:0001104659-21-093671:0
20,000 股@ US$1.014.8% 占其流量Common StockSEC:0001104659-21-093670:0
20 条申报中的 20 条
About Esposito Pamela
Esposito Pamela is Directeur Commercial and has filed 20 forms in total. Across the 20 sampled filings, the transactions recorded span 2021-07-19 to 2026-03-20, with EUR 0 in purchases and EUR 148122 in sales, and the most frequent transaction type is Levée d'options. The recent filings concern Kymera Therapeutics, Inc. and Replimune Group, Inc.
